Neuroprotective effect of lercanidipine in middle cerebral artery occlusion model of stroke in rats

Experimental Neurology

Volumn 288, Issue , 2017, Pages 25-37

  Gupta, Sangeetha ^a   Sharma, Uma ^a   Jagannathan, Naranamangalam R ^a   Gupta, Yogendra Kumar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anti apoptotic; Anti inflammatory; Anti oxidant; Calcium channel blocker; Lercanidipine; MCAo; Neuroprotection; Stroke

Indexed keywords

BIOCHEMICAL MARKER; CASPASE 3; CASPASE 9; GELATINASE A; GELATINASE B; GLUTATHIONE; LERCANIDIPINE; MALONALDEHYDE; NITRIC OXIDE; SUPEROXIDE DISMUTASE; TRIPHENYLTETRAZOLIUM; DIHYDROPYRIDINE DERIVATIVE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE MODEL; DRUG EFFICACY; DRUG EXPOSURE; GRIP STRENGTH TEST; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; NEUROLOGICAL DEFICIT SCORE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; REPEATED DRUG DOSE; REPERFUSION; ROTAROD TEST; SCORING SYSTEM; VASODILATATION; WISTAR RAT; ANIMAL; BLOOD PRESSURE; BRAIN CIRCULATION; COMPLICATION; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; INFARCTION, MIDDLE CEREBRAL ARTERY; LASER DOPPLER FLOWMETRY; METABOLISM; MOTOR ACTIVITY; NERVOUS SYSTEM DISEASES;

ANIMALS; BLOOD PRESSURE; BRAIN INFARCTION; CASPASE 3; CASPASE 9; CEREBROVASCULAR CIRCULATION; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION; INFARCTION, MIDDLE CEREBRAL ARTERY; LASER-DOPPLER FLOWMETRY; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 2; MOTOR ACTIVITY; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR;

EID: 84994608263     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2016.10.014     Document Type: Article

References (59)

1. Alexandrov, A.V., Sharma, V.K., Lao, A.Y., Tsivgoulis, G., Malkoff, M.D., Alexandrov, A.W., Reversed Robin Hood syndrome in acute ischemic stroke patients. Stroke 38:11 (2007), 3045–3048.
2. Andersen, J.K., Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 5:10 (2004), S18–S25.
3. Akpan, N., Serrano-Saiz, E., Zacharia, B.E., Otten, M.L., Ducruet, A.F., Snipas, S.J., Liu, W., Velloza, J., Cohen, G., Sosunov, S.A., Frey, W.H. 2nd, Salvesen, G.S., Connolly, E.S. Jr., Troy, C.M., Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke. J. Neurosci. 31:24 (2011), 8894–8904.
4. Barone, F.C., Lysko, P.G., Price, W.J., Feuerstein, G., al-Baracanji, K.A., Benham, C.D., Harrison, D.C., Harries, M.H., Bailey, S.J., Hunter, A.J., SB 201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischemia in rats and mice. Stroke 26:9 (1995), 1683–1689 (discussion 1689–1690).
5. Bederson, J.B., Pitts, L.H., Germano, S.M., Nishimura, M.C., Davis, R.L., Bartkowski, H.M., Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17:6 (1986), 1304–1308.
6. Borghi, C., Lercanidipine in hypertension. Vasc. Health Risk Manag. 1:3 (2005), 173–182.
7. Braughler, J.M., Burton, P.S., Chase, R.L., Pregenzer, J.F., Jacobsen, E.J., VanDoornik, F.J., Tustin, J.M., Ayer, D.E., Bundy, G.L., Novel membrane localized iron chelators as inhibitors of iron-dependent lipid peroxidation. Biochem. Pharmacol. 37:20 (1988), 3853–3860.
8. Broughton, B.R., Reutens, D.C., Sobey, C.G., Apoptotic mechanisms after cerebral ischemia. Stroke 40:5 (2009), e331–e339.
9. Castellanos, M., Leira, R., Serena, J., Pumar, J.M., Lizasoain, I., Castillo, J., Dávalos, A., Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 34:1 (2003), 40–46.
10. Chauhan, A., Sharma, U., Reeta, K.H., Jagannathan, N.R., Mehra, R.D., Gupta, Y.K., Neuroimaging, biochemical and cellular evidence of protection by mycophenolate mofetil on middle cerebral artery occlusion induced injury in rats. Eur. J. Pharmacol. 684:1–3 (2012), 71–78.
11. Chen, H., Yoshioka, H., Kim, G.S., Jung, J.E., Okami, N., Sakata, H., Maier, C.M., Narasimhan, P., Goeders, C.E., Chan, P.H., Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid. Redox Signal. 14:8 (2011), 1505–1517.
12. Chen, H.S., Chen, X.M., Feng, J.H., Liu, K.J., Qi, S.H., Shen, J.G., Peroxynitrite decomposition catalyst reduces delayed thrombolysis-induced hemorrhagic transformation in ischemia-reperfused rat brains. CNS Neurosci. Ther. 21:7 (2015), 585–590.
13. Cuadrado, E., Ortega, L., Hernández-Guillamon, M., Penalba, A., Fernández-Cadenas, I., Rosell, A., Montaner, J., Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J. Leukoc. Biol. 84:1 (2008), 207–214.
14. del Zoppo, G., Ginis, I., Hallenbeck, J.M., Iadecola, C., Wang, X., Feuerstein, G.Z., Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol. 10:1 (2000), 95–112.
15. Dirnagl, U., Kaplan, B., Jacewicz, M., Pulsinelli, W., Continuous measurement of cerebral cortical blood flow by laser-Doppler flowmetry in a rat stroke model. J. Cereb. Blood Flow Metab. 9:5 (1989), 589–596.
16. Dirnagl, U., Iadecola, C., Moskowitz, M.A., Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22:9 (1999), 391–397.
17. Ellman, G.L., Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82:1 (1959), 70–77.
18. Fernandez-Patron, C., Radomski, M.W., Davidge, S.T., Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ. Res. 85:10 (1999), 906–911.
19. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Pharmacol. Toxicol., 2005 (July).
20. Garry, P.S., Ezra, M., Rowland, M.J., Westbrook, J., Pattinson, K.T., The role of the nitric oxide pathway in brain injury and its treatment–from bench to bedside. Exp. Neurol. 263 (2015), 235–243.
21. Griess, P., Bemerkungen zu der abhandlung der H.H. Weselsky und Benedikt “Ueber einige azoverbindungen.”. Chem. Ber. 12 (1879), 426–428.
22. Gupta, Y.K., Briyal, S., Sharma, U., Jagannathan, N.R., Gulati, A., Effect of endothelin antagonist (TAK-044) on cerebral ischemic volume, oxidative stress markers and neurobehavioral parameters in the middle cerebral artery occlusion model of stroke in rats. Life Sci. 77 (2005), 15–27.
23. Hara, H., Huang, P.L., Panahian, N., Fishman, M.C., Moskowitz, M.A., Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J. Cereb. Blood Flow Metab. 16:4 (1996), 605–611.
24. Hedna, V.S., Ansari, S., Shahjouei, S., Cai, P.Y., Ahmad, A.S., Mocco, J., Qureshi, A.I., Validity of laser Doppler flowmetry in predicting outcome in murine intraluminal middle cerebral artery occlusion stroke. J. Vasc. Interv. Neurol. 8:3 (2015), 74–82.
25. Incandela, L., Belcaro, G., Cesarone, M.R., De Sanctis, M.T., Griffin, M., Cacchio, M., Nicolaides, A.N., Bucci, M., Barsotti, A., Martines, G., Cornelli, U., Di Renzo, A., Oxygen-free radical decrease in hypertensive patients treated with lercanidipine. Int. Angiol. 20:2 (2001), 136–140.
26. Kramer, M.S., Vinall, P.E., Katolik, L.I., Simeone, F.A., Comparison of cerebral blood flow measured by laser-Doppler flowmetry and hydrogen clearance in cats after cerebral insult and hypervolemic hemodilution. Neurosurgery 38:2 (1996), 355–361.
27. Larkin, J.G., Thompson, G.G., Scobie, G., Forrest, G., Drennan, J.E., Brodie, M.J., Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures. Epilepsia 33:4 (1992), 760–769.
28. 2 ⁺ signaling pathway in astrocytes ameliorates neuronal death and brain damage while reducing behavioral deficits after focal ischemic stroke. Cell Calcium 58:6 (2015), 565–576.
29. Lo, E.H., Broderick, J.P., Moskowitz, M.A., tPA and proteolysis in the neurovascular unit. Stroke 35:2 (2004), 354–356.
30. Longa, E.Z., Weinstein, P.R., Carlson, S., Cummins, R., Reversible middle cerebral artery occlusion without craniotomy in rats. Stroke 20 (1989), 84–91.
31. Lu, Z.Q., Deng, Y.J., Lu, J.X., Effect of aloe polysaccharide on caspase-3 expression following cerebral ischemia and reperfusion injury in rats. Mol. Med. Rep. 6:2 (2012), 371–374.
32. Lutsep, H.L., Clark, W.M., Current status of neuroprotective agents in the treatment of acute ischemic stroke. Curr. Neurol. Neurosci. Rep. 1:1 (2001), 13–18.
33. Marklund, S., Marklund, G., Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem. 47:3 (1974), 469–474.
34. Martinez, M.L., Rizzi, E., Castro, M.M., Fernandes, K., Bendhack, L.M., Gerlach, R.F., Tanus-Santos, J.E., Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur. J. Pharmacol. 599:1–3 (2008), 110–116.
35. Martinez, M.L., Castro, M.M., Rizzi, E., Fernandes, K., Demacq, C., Bendhack, L.M., Gerlach, R.F., Tanus-Santos, J.E., Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur. J. Pharmacol. 591:1–3 (2008), 224–230.
36. Menne, J., Park, J.K., Agrawal, R., Lindschau, C., Kielstein, J.T., Kirsch, T., Marx, A., Muller, D., Bahlmann, F.H., Meier, M., Bode-Böger, S.M., Haller, H., Fliser, D., Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. FASEB J. 20:7 (2006), 994–996.
37. Middlemiss, D.N., Spedding, M., A functional correlate for the dihydropyridine binding site in rat brain. Nature 314:6006 (1985), 94–96.
38. Milanlioglu, A., Aslan, M., Ozkol, H., Çilingir, V., Nuri Aydin, M., Karadas, S., Serum antioxidant enzymes activities and oxidative stress levels in patients with acute ischemic stroke: influence on neurological status and outcome. Wien. Klin. Wochenschr. 128:5–6 (2016), 169–174.
39. Moran, P.M., Higgins, L.S., Cordel, B., Moser, P.C., Age related learning deficits in transgenic mice expressing the 721-amino acid isoform of human beta-amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 92:12 (1995), 5341–5345.
40. Moseley, M.E., Kucharczyk, J., Mintorovitch, J., Cohen, Y., Kurhanewicz, J., Derugin, N., Asgari, H., Norman, D., Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR Am. J. Neuroradiol. 11:3 (1990), 423–429.
41. Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., de Ferranti, S., Després, J-P., Fullerton, H.J., Howard, V.J., Huffman, M.D., Judd, S.E., Kissela, B.M., Lackland, D.T., Lichtman, J.H., Lisabeth, L.D., Liu, S., Mackey, R.H., Matchar, D.B., McGuire, D.K., Mohler, E.R. III, Moy, C.S., Muntner, P., Mussolino, M.E., Nasir, K., Neumar, R.W., Nichol, G., Palaniappan, L., Pandey, D.K., Reeves, M.J., Rodriguez, C.J., Sorlie, P.D., Stein, J., Towfighi, A., Turan, T.N., Virani, S.S., Willey, J.Z., Woo, D., Yeh, R.W., Turner, M.B., on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association Circulation., 131, 2015, e29–e322.
42. Nicole, O., Docagne, F., Ali, C., Margaill, I., Carmeliet, P., MacKenzie, E.T., Vivien, D., Buisson, A., The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7:1 (2001), 59–64.
43. Ohkawa, H., Ohishi, N., Yagi, K., Assay of lipid peroxides in animals tissue by thiobarbituric acid reaction. Anal. Biochem. 95:2 (1979), 351–358.
44. Rami, A., Bechmann, I., Stehle, J.H., Exploiting endogenous anti-apoptotic proteins for novel therapeutic strategies in cerebral ischemia. Prog. Neurobiol. 85 (2008), 273–296.
45. Rogers, D.C., Campbell, C.A., Stretton, J.L., Mackay, K.B., Correlation between motor impairment and infarct volume after permanent and transient middle artery occlusion in the rat. Stroke 28:10 (1997), 2060–2065.
46. Rupadevi, M., Parasuraman, S., Raveendran, R., Protocol for middle cerebral artery occlusion by an intraluminal suture method. J. Pharmacol. Pharmacother. 2:1 (2011), 36–39.
47. Sakurai-Yamashita, Y., Harada, N., Niwa, M., Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP. Cell. Mol. Neurobiol. 31:4 (2011), 561–567.
48. Sasaki, T., Maruyama, H., Kase, Y., Takeda, S., Aburada, M., Antianginal effects of lercanidipine on the vasopressin or methacholine induced anginal model in rats. Biol. Pharm. Bull. 28:5 (2005), 811–816.
49. Sawicki, G., Salas, E., Murat, J., Miszta-Lane, H., Radomski, M.W., Release of gelatinase a during platelet activation mediates aggregation. Nature 386 (1997), 616–619.
50. Siesjö, B.K., Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology. (1992). J. Neurosurg. 108 (2008), 616–631.
51. Siesjö, B.K., Zhao, Q., Pahlmark, K., Siesjö, P., Katsura, K., Folbergrová, J., Glutamate, calcium, and free radicals as mediators of ischemic brain damage. Ann. Thorac. Surg. 59:5 (1995), 1316–1320.
52. Song, J., Park, J., Oh, Y., Lee, J.E., Glutathione suppresses cerebral infarct volume and cell death after ischemic injury: involvement of FOXO3 inactivation and Bcl2 expression. Oxidative Med. Cell. Longev. 2015 (2015), 426069–426070.
53. Swanson, R.A., Morton, M.T., Tsao-Wu, G., Savalos, R.A., Davidson, C., Sharp, F.R., A semiautomated method for measuring brain infarct volume. J. Cereb. Blood Flow Metab. 10:2 (1990), 290–293.
54. Tatlisumak, T., Carano, R.A., Takano, K., Opgenorth, T.J., Sotak, C.H., Fisher, M., A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: a diffusion and perfusion MRI study. Stroke 29:4 (1998), 850–857.
55. Wang, L., Yushmanov, V.E., Liachenko, S.M., Tang, P., Hamilton, R.L., Xu, Y., Late reversal of cerebral perfusion and water diffusion after transient focal ischemia in rats. J. Cereb. Blood Flow Metab. 22:3 (2002), 253–261.
56. Wang, Q., Tang, X.N., Yenari, M.A., The inflammatory response in stroke. J. Neuroimmunol. 184:1–2 (2007), 53–68.
57. White, B.C., Sullivan, J.M., DeGracia, D.J., O'Neil, B.J., Neumar, R.W., Grossman, L.I., Rafols, J.A., Krause, G.S., Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J. Neurol. Sci. 179:S 1-2 (2000), 1–33.
58. Wu, J.R., Liou, S.F., Lin, S.W., Chai, C.Y., Dai, Z.K., Liang, J.C., Chen, I.J., Yeh, J.L., Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling. Pharmacol. Res. 59:1 (2009), 48–56.
59. Yeh, J.L., Hsu, J.H., Liang, J.C., Chen, I.J., Liou, S.F., Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-γ-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities. Atherosclerosis 226:2 (2013), 364–372.